Photocatalytic degradation of endocrine disruptor compounds under simulated solar light
Metadatos
Mostrar el registro completo del ítemAutor
Maroga Mboula, V.; Héquet, V.; Andrès, Y.; Pastrana Martínez, Luisa María; Doña-Rodríguez, J.M; Silva, A.M.T.; Falaras, P.Editorial
Elsevier
Fecha
2013-08-01Referencia bibliográfica
Water Research Volume 47, Issue 12, 2013, Pages 3997-4005
Patrocinador
We are grateful for the funding of the European Commission through the Clean Water Project which is a Collaborative Project (Grant Agreement number 227017) co-funded by the Research DG of the European Commission within the joint RTD activities of the Environment and NMP Thematic PrioritiesResumen
Nanostructured titanium materials with high UV-visible activity were synthesized in the collaborative project Clean Water FP7. In this study, the efficiency of some of these catalysts to degrade endocrine disruptor compounds, using bisphenol A as the model compound, was evaluated. Titanium dioxide P25 (AEROXIDE® TiO2, Evonik Degussa) was used as the reference. The photocatalytic degradation was carried out under the UV part of a simulated solar light (280–400 nm) and under the full spectrum of a simulated solar light (200 nm-30 μm). Catalytic efficiency was assessed using several indicators such as the conversion yield, the mineralization yield, by-product formation and the endocrine disruption effect of by-products. The new synthesized catalysts exhibited a significant degradation of bisphenol A, with the so-called ECT-1023t being the most efficient. The intermediates formed during photocatalytic degradation experiments with ECT-1023t as catalyst were monitored and identified. The estrogenic effect of the intermediates was also evaluated in vivo using a ChgH-GFP transgenic medaka line. The results obtained show that the formation of intermediates is related to the nature of the catalyst and depends on the experimental conditions. Moreover, under simulated UV, in contrast with the results obtained using P25, the by-products formed with ECT-1023t as catalyst do not present an estrogenic effect.